Pre-made Tezepelumab benchmark antibody ( Whole mAb, anti-TSLP therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Tezepelumab biosimilar, Whole Mab: Anti-TSLP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tezepelumab (INN; development codes MEDI9929 and AMG 157) is a human monoclonal antibody designed for the treatment of asthma and atopic dermatitis. It blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.
| Products Name (INN Index) | Pre-Made Tezepelumab biosimilar, Whole Mab: Anti-TSLP therapeutic antibody |
|---|---|
| INN Name | Tezepelumab |
| Target | TSLP |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | 5j13:CB |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Amgen,AstraZeneca,Bispebjerg Hospital,Lund University,MedImmune,University of Copenhagen,University of Newcastle in Australia |
| Conditions Approved | NA |
| Conditions Active | Asthma,Atopic dermatitis,Rhinosinusitis,Chronic obstructive pulmonary disease |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TSLP |
| Package |
